DaShenLin Pharmaceutical Group Co., Ltd. (SHA:603233)
China flag China · Delayed Price · Currency is CNY
18.50
-0.35 (-1.86%)
Aug 3, 2026, 3:00 PM CST

SHA:603233 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
26,86226,84525,86123,93120,78016,759
Other Revenue
657.1657.1635.56599.94467.67-
27,51927,50226,49724,53121,24816,759
Revenue Growth
3.07%3.79%8.01%15.45%26.78%14.92%
Cost of Revenue
18,02918,09217,42215,79513,22610,385
Gross Profit
9,4919,4109,0748,7368,0226,374
Selling, General & Admin
7,2347,2157,4246,8086,2705,187
Research & Development
42.0941.2751.6880.9374.3844.61
Other Operating Expenses
126.4105.2335.4735.3264.5729.94
Operating Expenses
7,4157,3757,5276,9406,4325,273
Operating Income
2,0762,0361,5471,7961,5901,101
Interest Expense
-171.44-189.38-248.83-239.26-231.97-212.04
Interest & Investment Income
65.6669.682.2391.7568.8977.7
Currency Exchange Gain (Loss)
-0.7-0.70.32---
Other Non Operating Income (Expenses)
-33.11-34.45-46.64-49.85-48.52-29.15
EBT Excluding Unusual Items
1,9371,8811,3351,5991,379937.76
Impairment of Goodwill
-53.58-53.58-38.6-6.21--
Gain (Loss) on Sale of Investments
-5.45-1.5210.614.38-18.7134.57
Gain (Loss) on Sale of Assets
18.0414.719.213.4318.735.63
Asset Writedown
4.91-----
Other Unusual Items
6.369.113.8927.0536.3665.94
Pretax Income
1,9071,8491,3401,6281,4151,044
Income Tax Expense
502.24490.53359.73397.12335.62239.52
Earnings From Continuing Operations
1,4051,359979.941,2311,079804.39
Minority Interest in Earnings
-118.42-123.67-65.19-64.16-43.55-13.16
Net Income
1,2861,235914.751,1661,036791.23
Net Income to Common
1,2861,235914.751,1661,036791.23
Net Income Growth
31.76%35.04%-21.58%12.63%30.90%-25.51%
Shares Outstanding (Basic)
1,1401,1441,1291,1331,1381,130
Shares Outstanding (Diluted)
1,1401,1441,1291,1331,1381,130
Shares Change
0.71%1.28%-0.28%-0.50%0.69%-0.24%
EPS (Basic)
1.131.080.811.030.910.70
EPS (Diluted)
1.131.080.811.030.910.70
EPS Growth
30.84%33.33%-21.36%13.19%30.00%-25.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
4,0374,8651,6261,3772,722260.05
Free Cash Flow Per Share
3.544.251.441.222.390.23
Dividend Per Share
0.8300.8300.6200.3100.5000.347
Dividend Growth
33.87%33.87%100.00%-38.00%43.97%-24.99%
Gross Margin
34.49%34.22%34.25%35.61%37.76%38.03%
Operating Margin
7.54%7.40%5.84%7.32%7.48%6.57%
Profit Margin
4.67%4.49%3.45%4.75%4.87%4.72%
Free Cash Flow Margin
14.67%17.69%6.14%5.61%12.81%1.55%
EBITDA
2,3402,3021,8243,2441,8081,306
EBITDA Margin
8.50%8.37%6.88%13.22%8.51%7.79%
D&A For EBITDA
264.04266.52276.411,448218.06204.62
EBIT
2,0762,0361,5471,7961,5901,101
EBIT Margin
7.54%7.40%5.84%7.32%7.48%6.57%
Effective Tax Rate
26.34%26.52%26.85%24.40%23.72%22.94%
Revenue as Reported
27,51927,50226,49724,53121,24816,759
Advertising Expenses
--25.4930.8126.27-